These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 29772196)

  • 1. Ataxin-2 Is Droppin' Some Knowledge.
    Becker LA; Gitler AD
    Neuron; 2018 May; 98(4):673-675. PubMed ID: 29772196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNP-Granule Assembly via Ataxin-2 Disordered Domains Is Required for Long-Term Memory and Neurodegeneration.
    Bakthavachalu B; Huelsmeier J; Sudhakaran IP; Hillebrand J; Singh A; Petrauskas A; Thiagarajan D; Sankaranarayanan M; Mizoue L; Anderson EN; Pandey UB; Ross E; VijayRaghavan K; Parker R; Ramaswami M
    Neuron; 2018 May; 98(4):754-766.e4. PubMed ID: 29772202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structured and disordered regions of Ataxin-2 contribute differently to the specificity and efficiency of mRNP granule formation.
    Petrauskas A; Fortunati DL; Kandi AR; Pothapragada SS; Agrawal K; Singh A; Huelsmeier J; Hillebrand J; Brown G; Chaturvedi D; Lee J; Lim C; Auburger G; VijayRaghavan K; Ramaswami M; Bakthavachalu B
    PLoS Genet; 2024 May; 20(5):e1011251. PubMed ID: 38768217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A C-terminal ataxin-2 disordered region promotes Huntingtin protein aggregation and neurodegeneration in Drosophila models of Huntington's disease.
    Huelsmeier J; Walker E; Bakthavachalu B; Ramaswami M
    G3 (Bethesda); 2021 Dec; 11(12):. PubMed ID: 34718534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antagonistic roles for Ataxin-2 structured and disordered domains in RNP condensation.
    Singh A; Hulsmeier J; Kandi AR; Pothapragada SS; Hillebrand J; Petrauskas A; Agrawal K; Rt K; Thiagarajan D; Jayaprakashappa D; VijayRaghavan K; Ramaswami M; Bakthavachalu B
    Elife; 2021 Mar; 10():. PubMed ID: 33689682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice.
    Becker LA; Huang B; Bieri G; Ma R; Knowles DA; Jafar-Nejad P; Messing J; Kim HJ; Soriano A; Auburger G; Pulst SM; Taylor JP; Rigo F; Gitler AD
    Nature; 2017 Apr; 544(7650):367-371. PubMed ID: 28405022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Motor neurone disease/amyotrophic lateral sclerosis associated with intermediate-length CAG repeat expansions in Ataxin-2 does not have 1C2-positive polyglutamine inclusions.
    Highley JR; Lorente Pons A; Cooper-Knock J; Wharton SB; Ince PG; Shaw PJ; Wood J; Kirby J
    Neuropathol Appl Neurobiol; 2016 Jun; 42(4):377-89. PubMed ID: 26095883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Taking a risk: a therapeutic focus on ataxin-2 in amyotrophic lateral sclerosis?
    van den Heuvel DM; Harschnitz O; van den Berg LH; Pasterkamp RJ
    Trends Mol Med; 2014 Jan; 20(1):25-35. PubMed ID: 24140266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pur-alpha functionally interacts with FUS carrying ALS-associated mutations.
    Di Salvio M; Piccinni V; Gerbino V; Mantoni F; Camerini S; Lenzi J; Rosa A; Chellini L; Loreni F; Carrì MT; Bozzoni I; Cozzolino M; Cestra G
    Cell Death Dis; 2015 Oct; 6(10):e1943. PubMed ID: 26492376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicity of pathogenic ataxin-2 in Drosophila shows dependence on a pure CAG repeat sequence.
    McGurk L; Rifai OM; Shcherbakova O; Perlegos AE; Byrns CN; Carranza FR; Zhou HW; Kim HJ; Zhu Y; Bonini NM
    Hum Mol Genet; 2021 Sep; 30(19):1797-1810. PubMed ID: 34077532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Futsch/MAP1B mRNA is a translational target of TDP-43 and is neuroprotective in a Drosophila model of amyotrophic lateral sclerosis.
    Coyne AN; Siddegowda BB; Estes PS; Johannesmeyer J; Kovalik T; Daniel SG; Pearson A; Bowser R; Zarnescu DC
    J Neurosci; 2014 Nov; 34(48):15962-74. PubMed ID: 25429138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ataxin-2 interacts with FUS and intermediate-length polyglutamine expansions enhance FUS-related pathology in amyotrophic lateral sclerosis.
    Farg MA; Soo KY; Warraich ST; Sundaramoorthy V; Blair IP; Atkin JD
    Hum Mol Genet; 2013 Feb; 22(4):717-28. PubMed ID: 23172909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ALS-associated ataxin 2 polyQ expansions enhance stress-induced caspase 3 activation and increase TDP-43 pathological modifications.
    Hart MP; Gitler AD
    J Neurosci; 2012 Jul; 32(27):9133-42. PubMed ID: 22764223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ataxin-2 and its Drosophila homolog, ATX2, physically assemble with polyribosomes.
    Satterfield TF; Pallanck LJ
    Hum Mol Genet; 2006 Aug; 15(16):2523-32. PubMed ID: 16835262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting RTN4/NoGo-Receptor reduces levels of ALS protein ataxin-2.
    Rodriguez CM; Bechek SC; Jones GL; Nakayama L; Akiyama T; Kim G; Solow-Cordero DE; Strittmatter SM; Gitler AD
    Cell Rep; 2022 Oct; 41(4):111505. PubMed ID: 36288715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CAG repeats ≥ 34 in Ataxin-1 gene are associated with amyotrophic lateral sclerosis in a Brazilian cohort.
    Gonçalves JPN; de Andrade HMT; Cintra VP; Bonadia LC; Leoni TB; de Albuquerque M; Martins MP; de Borba FC; Couteiro RED; de Oliveira DS; Claudino R; Gonçalves MVM; Dourado ME; de Souza LC; Teixeira AL; de Godoy Rousseff Prado L; Tumas V; Oliveira ASB; Nucci A; Lopes-Cendes I; Marques W; França MC
    J Neurol Sci; 2020 Jul; 414():116842. PubMed ID: 32339968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative interactomics analysis of different ALS-associated proteins identifies converging molecular pathways.
    Blokhuis AM; Koppers M; Groen EJN; van den Heuvel DMA; Dini Modigliani S; Anink JJ; Fumoto K; van Diggelen F; Snelting A; Sodaar P; Verheijen BM; Demmers JAA; Veldink JH; Aronica E; Bozzoni I; den Hertog J; van den Berg LH; Pasterkamp RJ
    Acta Neuropathol; 2016 Aug; 132(2):175-196. PubMed ID: 27164932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drosophila Ref1/ALYREF regulates transcription and toxicity associated with ALS/FTD disease etiologies.
    Berson A; Goodman LD; Sartoris AN; Otte CG; Aykit JA; Lee VM; Trojanowski JQ; Bonini NM
    Acta Neuropathol Commun; 2019 Apr; 7(1):65. PubMed ID: 31036086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PARylation regulates stress granule dynamics, phase separation, and neurotoxicity of disease-related RNA-binding proteins.
    Duan Y; Du A; Gu J; Duan G; Wang C; Gui X; Ma Z; Qian B; Deng X; Zhang K; Sun L; Tian K; Zhang Y; Jiang H; Liu C; Fang Y
    Cell Res; 2019 Mar; 29(3):233-247. PubMed ID: 30728452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitigating a TDP-43 proteinopathy by targeting ataxin-2 using RNA-targeting CRISPR effector proteins.
    Zeballos C MA; Moore HJ; Smith TJ; Powell JE; Ahsan NS; Zhang S; Gaj T
    Nat Commun; 2023 Oct; 14(1):6492. PubMed ID: 37838698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.